Minerva Neurosciences Secures $80M Financing to Advance Schizophrenia Drug Trial
Event summary
- Minerva Neurosciences raised $80M in October 2025 via private placement, with potential for additional $120M from warrant exercises.
- Roluperidone Phase 3 trial for negative symptoms of schizophrenia set to begin in Q2 2026, with results expected in 2H 2027.
- Company's cash position improved to $82.4M as of December 31, 2025, up from $21.5M a year earlier.
- GAAP net loss for 2025 was $293.4M, but non-GAAP adjusted net loss was $16.0M.
- Warrant liability stood at $171.5M as of December 31, 2025.
The big picture
Minerva's strategic financing positions it to advance its lead candidate, roluperidone, through a critical Phase 3 trial for schizophrenia. The company's alignment with FDA on trial design reduces regulatory risk, but the biotech sector's high failure rates and competitive landscape remain significant challenges. Success with roluperidone could shift treatment paradigms for negative symptoms of schizophrenia, a substantial unmet medical need.
What we're watching
- Trial Execution
- Whether Minerva can successfully complete the Phase 3 trial for roluperidone and achieve positive results by 2H 2027.
- Funding Sufficiency
- The pace at which Minerva will need to secure additional financing if warrant exercises do not materialize as expected.
- Regulatory Pathway
- How FDA alignment will impact the resubmission of the New Drug Application and potential approval timeline for roluperidone.
Related topics